Candidate Molecules definition

Candidate Molecules means, collectively, monoclonal antibody ("mAb") HUIV26 and mAb HUI77 as provided by Bio-Management to Ixsys hereunder.
Sample 1Sample 2Sample 3

Examples of Candidate Molecules in a sentence

  • Ixsys shall optimize and humanize the Candidate Molecules as set forth in the Research Plan.

  • Second, in reference to your letter to CPI shareholders dated May 16, 2005, in which you stated that you were "not able to take a position on the Tender Offer", you fail to disclose any benefits to accepting the Tender Offer, much less the most obvious reason in favor of accepting the Tender Offer.

  • SANOFI By: /s/ Xxxx Xxxxxxxx By: /s/ [*] Printed Name: Xxxx Xxxxxxxx Printed Name: [*] Title: CEO Title: [*] Date: 9/7/2018 Date: 7/8/2018 Exhibit 1 Feasibility Study Agreement Candidate Molecules Molecule No 1 [*] Molecule No 2 [*] Molecule No 3 [*] Molecule No 4 [*] Molecule No 5 [*] Molecule No 6 [*] Molecule No 7 [*] Annex 2 Press Release Dyadic International, Inc.

  • Ixsys shall not use the Program Antibodies, or the suboptimized and humanized compositions of matter derived by Ixsys from the Candidate Molecules under the Program (or the cDNA encoding such compositions of matter), for any purpose other than the performance of its obligations under this Agreement.

  • For the emergence of the rights and responsibilities of parents and children under the general rule are simultaneous be these two signs.

  • CMI shall have the right (in its sole discretion), exercisable by giving AME express written notice of such exercise prior to August 15, 2000, to extend the Program Term with respect to the following Candidate Molecules: mAb XL313 and mAb FM155, for the period commencing on the date within ninety (90) days following the date AME timely receives such notice of exercise from CMI and continuing for the subsequent seven (7) months.

  • Bio-Management shall pay to Ixsys *** each for the humanization and optimization of each of the two (2) Candidate Molecules, to be paid *** starting from the Effective Date.

  • The public authorities should provide the national minorities the opportunity to exert influence on issues which concern them and as far as possible consult with the representatives of the minorities on such issues.

  • Bio-Management shall pay to Ixsys [***] each for the humanization and optimization of each of the two (2) Candidate Molecules, to be paid in equal quarterly installments over the six (6) months starting from the Effective Date.

  • In addition to the global data, one can search HA flows by country.

Related to Candidate Molecules

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Development Candidate means a Collaboration Compound designated by Biogen Idec as a Development Candidate in accordance with Section 2.6.

  • Product Candidate means any pharmaceutical product developed, manufactured and/or tested by or on behalf of the Company that has not received a Regulatory Authorization for commercial distribution other than in connection with pre-clinical or clinical trials.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Licensed Compound means [***].

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Compounds means any or all of the following chemicals, as the context requires:

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

  • Therapeutic diet means meals served that are soft, low-fat, low-sodium or controlled calorie.

  • Diagnostic Product means any test or assay for diagnosing or detecting a disease, disorder, medical condition, or symptom.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Opioid antidote means any drug, regardless of dosage amount or method of administration, which has been approved by the United States Food and Drug Administration (FDA) for the treatment of an opioid overdose. “Opioid antidote” includes, but is not limited to, naloxone hydrochloride, in any dosage amount, which is administered through nasal spray or any other FDA-approved means or methods.

  • Gene Therapy means a product or service for the treatment or prevention of a disease that utilizes ex vivo or in vivo delivery (via viral or nonviral gene transfer methods or systems) of Genetic Material, including any cell incorporating Genetic Material.

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • Commercialization or “Commercialize” means activities directed to marketing, promoting, research and development as required, manufacturing for sale, offering for sale, distributing, importing or selling a product, including sub-licensing or sub-contracting of these activities.

  • Antigen means a substance recognized by the body as being foreign; it results in the production of specific antibodies directed against it.

  • Opioid antagonist means a drug that binds to opioid

  • Clinical Studies means human clinical trials for a Licensed Product and any other tests and studies for a Licensed Product in human subjects.

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • Clinical Study means a Phase I Study, Phase II Study, Phase III Study, or Pivotal Study, as applicable; but excluding any Post-Approval Studies.

  • Nicotine product means a product that contains nicotine and is not any of the following:

  • Biological product means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.